Long-term Extension Trial of Asenapine in Subjects With Schizophrenia (Study P06125)

• Sponsor: Organon and Co (Industry)
• Overall Status: Completed
• CT.gov ID: NCT01142596
• Collaborator: Meiji Seika Pharma Co., Ltd. (Industry)
• Enrollment: 201
• Arms: 2
• Actual Duration (Months): 58.9

Study Details

Study Description

Brief Summary

This is a multi-site, randomized fixed-flexible dose long-term study of asenapine in participants with schizophrenia. The first six weeks of the study will be double-blind and the remainder of the study will be open label. Participants in this study consist of participants who have completed the preceding short-term study (P06124 [NCT01098110]), who meet the inclusion criteria and wish to continue receiving study drug, and whom the investigators have deemed eligible for study participation. Participants who were on placebo twice daily (BID) in core trial P06124 will get placebo for the first 2 weeks then 5 mg asenapine BID for the next 4 weeks of double blind treatment, and will be re-randomized after week 6 to asenapine 5 mg BID or asenapine 10 mg BID. Participants who were on asenapine 5 mg BID in core trial P06124 will be re-randomized after Week 6 to asenapine 5 mg BID or asenapine 10 mg BID. Participants who were on asenapine 10 mg BID in core trial P06124 will be re-randomized after Week 6 to asenapine 5 mg BID or asenapine 10 mg BID. After re-randomization, drug will be administered open-label for 46 weeks. During this period dose is flexible can be adjusted using dose options of 5 and 10 mg BID for efficacy and tolerability.

Condition or Disease	Intervention/Treatment	Phase
Schizophrenia	Drug: Asenapine; Drug: Placebo	Phase 3

Study Design

• Study Type: Interventional
• Actual Enrollment: 201 participants
• Allocation: Randomized
• Intervention Model: Parallel Assignment
• Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
• Primary Purpose: Treatment
• Official Title: Long-term Extension Trial of Asenapine in Subjects With Schizophrenia (Phase 3 ; Protocol No. P06125)
• Actual Study Start Date: May 25, 2010
• Actual Primary Completion Date: Apr 22, 2015
• Actual Study Completion Date: Apr 22, 2015

Arms and Interventions

Arm	Intervention/Treatment
Experimental: Asenapine 5 mg BID Participants continue in the same arm they were on in core trial P06124 (except placebo arm starts 5 mg BID at Week 2) and will be re-randomized after Week 6 to asenapine 5 mg BID or asenapine 10 mg BID, administered open-label for 46 weeks. Open label dose can be adjusted using dose options of 5 and 10 mg BID for efficacy and tolerability	Drug: Asenapine; Asenapine 5 mg sublingual tablet BID, Asenapine 10 mg sublingual tablet BID; Other Names: SCH 900274 ; Drug: Placebo; Placebo sublingual tablet BID (first 2 weeks, participants who were in placebo arm of P06124 study only)
Experimental: Asenapine 10 mg BID Participants continue in the same arm they were on in core trial P06124 (except placebo arm starts 5 mg bid at Week 2) and will be re-randomized after Week 6 to asenapine 5 mg BID or asenapine 10 mg BID, administered open-label for 46 weeks. Open label dose can be adjusted using dose options of 5 and 10 mg BID for efficacy and tolerability	Drug: Asenapine; Asenapine 5 mg sublingual tablet BID, Asenapine 10 mg sublingual tablet BID; Other Names: SCH 900274 ; Drug: Placebo; Placebo sublingual tablet BID (first 2 weeks, participants who were in placebo arm of P06124 study only)

Outcome Measures

Primary Outcome Measures

1. Percentage of Participants in Categories of Change in Weight From Study P06124 Baseline to Final Assessment [Study P06124 baseline and P06125 study from Day 1 up to Week 52]

   For each participant, change in weight from preceding 6-week double-blind Study P06124 baseline to the final assessment of extension study P06125 was determined (calculated as final assessment value minus baseline value). Final assessment was last evaluation of participant in study, whether participant completed or did not complete study. Participants were allocated to categories of percentage change from defined baseline to final assessment.

2. Percentage of Participants in Categories of Change in Weight From Study P06125 Baseline to Final Assessment [Study P06125 baseline up to Week 52]

   For each participant, change in weight from extension study P06125 baseline to the final assessment of extension study was determined (calculated as final assessment value minus baseline value). Final assessment was last evaluation of participant in study, whether participant completed or did not complete study. Participants were allocated to categories of percentage change from defined baseline to final assessment.

3. Change From Study P06124 Baseline in Body Mass Index (BMI) at Week 52 [Study P06124 baseline and study P06125 Week 52]

   For each participant, change in BMI from preceding 6-week double-blind Study P06124 baseline to Week 52 of extension study P06125 was determined (calculated as Week 52 value minus baseline value).

4. Change From Study P06125 Baseline in BMI at Week 52 [Study P06125 baseline and Week 52]

   For each participant, change in BMI from extension study P06125 baseline to Week 52 of extension study was determined (calculated as Week 52 value minus baseline value).

5. Number of Participants With Extrapyramidal Symptoms [Up to 30 days after last dose of study drug (Up to approximately 56 weeks)]

   This measure reports the overall number of participants with any of a group of adverse events that were defined to represent extrapyramidal symptoms. The number of participants with each of the individual adverse events within this definition is also presented, for terms that occurred in at least one participant. For this measure, all adverse event terms within the Medical Dictionary for Regulatory Activities (MedDRA) Standardized MedDRA Query (SMQ) for "extrapyramidal syndrome" were treated as extrapyramidal symptoms.

6. Change From Study P06124 Baseline in Drug-Induced Extrapyramidal Symptoms Scale (DIEPSS) Total Score at Endpoint [Study P06124 baseline and P06125 study from Day 1 up to Week 52]

   Change in DIEPSS Total Score from preceding 6-week double-blind Study P06124 baseline to endpoint assessment of extension study P06125 was determined (calculated as endpoint value minus baseline value). Endpoint assessment was last evaluation of participant for this measure in study, whether participant completed or did not complete study. DIEPSS is a scale, rated by the investigator or rater appointed by the investigator, used to evaluate the severity of drug induced extrapyramidal symptoms occurring during antipsychotic drug treatment. It consists of 9 items: Items 1 through 8 assess individual symptoms; Item 9 is an assessment of global severity. Items 1 through 8 are classified into 4 categories of parkinsonism, akathisia, dystonia and dyskinesia. Each item is rated from 0 (none, normal) to 4 (severe). The Total Score is the sum of scores on Items 1 through 8, with a range from 0 (normal) to 32 (severe). Negative values of change from baseline represent improvement in symptoms.

7. Change From Study P06125 Baseline in DIEPSS Total Score at Endpoint [Study P06125 baseline up to Week 52]

   Change in DIEPSS Total Score from extension study P06125 baseline to the endpoint assessment of extension study was determined (calculated as endpoint value minus baseline value). Endpoint assessment was last evaluation of participant for this measure in study, whether participant completed or did not complete study. DIEPSS is a scale, rated by the investigator or rater appointed by the investigator, used to evaluate the severity of drug induced extrapyramidal symptoms occurring during antipsychotic drug treatment. It consists of 9 items: Items 1 through 8 assess individual symptoms; Item 9 is an assessment of global severity. Items 1 through 8 are classified into 4 categories of parkinsonism, akathisia, dystonia and dyskinesia. Each item is rated from 0 (none, normal) to 4 (severe). The Total Score is the sum of scores on Items 1 through 8, with a range from 0 (normal) to 32 (severe). Negative values of change from baseline represent improvement in symptoms.

8. Change From Study P06124 Baseline in DIEPSS Item 9 Score at Endpoint [Study P06124 baseline and P06125 study from Day 1 up to Week 52]

   Change in DIEPSS Item 9 (Global) Score from preceding 6-week double-blind Study P06124 baseline to endpoint assessment of extension study P06125 was determined (calculated as endpoint value minus baseline value). Endpoint assessment was last evaluation of participant for this measure in study, whether participant completed or did not complete study. DIEPSS is a scale, rated by the investigator or rater appointed by the investigator, used to evaluate the severity of drug induced extrapyramidal symptoms occurring during antipsychotic drug treatment. It consists of 9 items: Items 1 through 8 assess individual symptoms; Item 9 is an assessment of global severity. Each item is rated from 0 (none, normal) to 4 (severe). Negative values of change from baseline represent improvement in symptoms.

9. Change From Study P06125 Baseline in DIEPSS Item 9 Score at Endpoint [Study P06125 baseline up to Week 52]

   Change in DIEPSS Item 9 (Global) Score from extension study P06125 baseline to the endpoint assessment of extension study was determined (calculated as endpoint value minus baseline value). Endpoint assessment was last evaluation of participant for this measure in study, whether participant completed or did not complete study. DIEPSS is a scale, rated by the investigator or rater appointed by the investigator, used to evaluate the severity of drug induced extrapyramidal symptoms occurring during antipsychotic drug treatment. It consists of 9 items: Items 1 through 8 assess individual symptoms; Item 9 is an assessment of global severity. Each item is rated from 0 (none, normal) to 4 (severe). Negative values of change from baseline represent improvement in symptoms.

10. Change From Study P06124 Baseline in Glycosylated Hemoglobin (HbA1c) at Week 52 [Study P06124 baseline and study P06125 Week 52]

    For each participant, change in HbA1c from preceding 6-week double-blind Study P06124 baseline to Week 52 of extension study P06125 was determined (calculated as Week 52 value minus baseline value).

11. Change From Study P06125 Baseline in HbA1c at Week 52 [Study P06125 baseline and Week 52]

    For each participant, change in HbA1c from extension study P06125 baseline to Week 52 of extension study was determined (calculated as Week 52 value minus baseline value).

12. Change From Study P06124 Baseline in Fasting Glucose at Week 52 [Study P06124 baseline and study P06125 Week 52]

    For each participant, change in fasting glucose from preceding 6-week double-blind Study P06124 baseline to Week 52 of extension study P06125 was determined (calculated as Week 52 value minus baseline value).

13. Change From Study P06125 Baseline in Fasting Glucose at Week 52 [Study P06125 baseline and Week 52]

    For each participant, change in fasting glucose from extension study P06125 baseline to Week 52 of extension study was determined (calculated as Week 52 value minus baseline value).

14. Change From Study P06124 Baseline in Insulin at Week 52 [Study P06124 baseline and study P06125 Week 52]

    For each participant, change in insulin from preceding 6-week double-blind Study P06124 baseline to Week 52 of extension study P06125 was determined (calculated as Week 52 value minus baseline value).

15. Change From Study P06125 Baseline in Insulin at Week 52 [Study P06125 baseline and Week 52]

    For each participant, change in insulin from extension study P06125 baseline to Week 52 of extension study was determined (calculated as Week 52 value minus baseline value).

16. Change From Study P06124 Baseline in Prolactin at Week 52 [Study P06124 baseline and study P06125 Week 52]

    For each participant, change in prolactin from preceding 6-week double-blind Study P06124 baseline to Week 52 of extension study P06125 was determined (calculated as Week 52 value minus baseline value).

17. Change From Study P06125 Baseline in Prolactin at Week 52 [Study P06125 baseline and Week 52]

    For each participant, change in prolactin from extension study P06125 baseline to Week 52 of extension study was determined (calculated as Week 52 value minus baseline value).

18. Number of Participants With Serious Adverse Events (AEs) [Up to 30 days after last dose of study drug (Up to approximately 56 weeks)]

    An AE is defined as any untoward medical occurrence in a participant administered study drug and which does not necessarily have to have a causal relationship with the study drug. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with study drug administration, whether or not considered related to study drug. A serious AE (SAE) is any AE occurring at any dose that results in death, is life-threatening, results in hospitalization or prolongation of hospitalization, results in persistent or significant disability/incapacity, or is a congenital anomaly/birth defect. In addition, an important medical event that may not result in death, be life-threatening, or require hospitalization may be considered an SAE when it may jeopardize the participant and may require medical or surgical intervention to prevent one of the outcomes listed in this definition.

19. Number of Participants With Non-serious AEs [Up to 30 days after last dose of study drug (Up to approximately 56 weeks)]

    An AE is defined as any untoward medical occurrence in a participant administered study drug and which does not necessarily have to have a causal relationship with the study drug. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with study drug administration, whether or not considered related to study drug. This measure presents the number of participants with at least one AEs that was non-serious (i.e., was not determined to be an SAE).

20. Percentage of Participants With Abnormalities on Electrocardiogram (ECG) at Study P06124 Baseline, Study P06125 Baseline and Week 52 [Study P06124 baseline and P06125 study baseline and Week 52]

    The percentage of participants with abnormal ECG findings is reported for three time points: 6-week double-blind study P06124 baseline, extension study P06125 baseline and extension study Week 52.

21. Number of Participants Who Took Antiparkinsonian Drugs [P06125 study from Day 1 up to Week 52]

    This measure presents the number of participants who used antiparkinsonian drugs started on or after the start of study treatment in extension study P06125. Antiparkinsonian drugs were defined as those categorized into the N04 code (antiparkinson drugs) of the World Health Organization (WHO) Anatomical Therapeutic Chemical (ATC) classification system.

22. Median Time to Loss of Effect in Responders [P06124 study baseline and Day 42, and P06125 study from Day 1 up to Week 52]

    Median time to loss of effect from P06125 extension study baseline was estimated using Kaplan-Meier product-limit method. Result reported in Responders, participants with ≥30% decrease from study P06124 baseline in Positive and Negative Syndrome Scale (PANSS, schizophrenia symptom scale) Total Score at the end of study P06124. Investigator or subinvestigator was to determine whether the study drug failed to maintain effect based on occurrence of any of the following: 1) Increase in PANSS Total Score ≥30% from P06125 extension study baseline, 2) Determination that participant's schizophrenic symptomatology had deteriorated requiring one or more of defined interventions (add new antipsychotic drug, increase in level of psychiatric outpatient care, or hospitalization/increase in level of hospitalization for psychiatric need), 3) Clinical Global Impression-Severity (CGI-S) score ≥6, 4) Discontinuation from study because of lack of efficacy, 5) AE/SAE of worsening of schizophrenia.

23. Median Time to Loss of Effect in Non-Responders [P06124 study baseline and Day 42, and P06125 study from Day 1 up to Week 52]

    Median time to loss of effect from P06125 extension study baseline was estimated using Kaplan-Meier product-limit method. Result reported in Non-Responders, participants without ≥30% decrease from study P06124 baseline in PANSS Total Score at the end of study P06124. Investigator or subinvestigator was to determine whether the study drug failed to maintain effect based on occurrence of any of the following: 1) Increase in PANSS Total Score ≥30% from P06125 extension study baseline, 2) Determination that participant's schizophrenic symptomatology had deteriorated requiring one or more of defined interventions (add new antipsychotic drug, increase in level of psychiatric outpatient care, or hospitalization/increase in level of hospitalization for psychiatric need), 3) Clinical Global Impression-Severity (CGI-S) score ≥6, 4) Discontinuation from study because of lack of efficacy, 5) AE/SAE of worsening of schizophrenia.

Eligibility Criteria

Criteria

• Ages Eligible for Study: 20 Years to 64 Years
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No

Inclusion Criteria:

• Participant has completed 42-day drug administration in the preceding short-term study (Protocol P06124), has exhibited efficacy (CGI-I at the completion of the preceding short-term study of markedly improved, moderately improved, or slightly improved), has no significant safety problems, and has been judged appropriate for study participation by the investigator.

• Male and female participants. Women who are of childbearing potential (i.e., not surgically sterile or post menopausal for at least 1 year) must use medically acceptable birth control. Medically acceptable birth control includes condoms (male or female) with or without a spermicidal agent, diaphragm or cervical cap with spermicide, medically prescribed IUD, insert or copper-containing IUD, hormone-releasing IUD, systemic hormonal contraceptives, and surgical sterilization (eg, hysterectomy or tubal ligation). Male participants must agree to use condoms during their participation in the study.

• Participant must have been explained the nature of the study by the investigator, and be able to provide written consent prior to the conduct of the tests/observation of the clinical study.

Exclusion Criteria:

• A participant must not have any clinically significant abnormal laboratory, vital sign, physical examination, or electrocardiogram (ECG) findings that, in the investigator's opinion, preclude the participant's participation in the study

• A participant must not have a positive pregnancy test or be planning to become pregnant during the term of the study;

• A participant must not receive antipsychotics, antidepressants, mood stabilizers, anti-epileptics, monoamine oxidase inhibitors, St. John's Wort, antiemetics that are dopamine antagonist, or traditional herbal medication for psychiatric symptoms at the baseline;

• A participant must not be at risk of harming themselves or others, in the investigator's opinion;

• A participant must not have been determined to be unsuitable by an investigator.

Contacts and Locations

Locations

No locations specified.

Sponsors and Collaborators

• Organon and Co
• Meiji Seika Pharma Co., Ltd.

Investigators

• Study Director: Medical Director, Merck Sharp & Dohme LLC

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.

• Responsible Party: Organon and Co
• ClinicalTrials.gov Identifier: NCT01142596
• Other Study ID Numbers: P06125; 132324
• First Posted: Jun 11, 2010
• Last Update Posted: Feb 7, 2022
• Last Verified: Feb 1, 2022

• Individual Participant Data (IPD) Sharing Statement: Yes
• Plan to Share IPD: Yes
• Additional relevant MeSH terms: Schizophrenia; Asenapine

Study Results

Participant Flow

Arm/Group Title	Placebo/Asenapine	Asenapine 5/10 mg BID
Arm/Group Description	Participants in this group had received double-blind placebo BID in preceding study P06124 (NCT01098110), and continued on same double-blind dose for first 2 weeks of extension study P06125, then took double-blind asenapine 5 mg BID for 4 weeks, after which were re-randomized to open label asenapine 5 or 10 mg BID for 46 weeks. Open label dose could be adjusted using dose options of 5 and 10 mg BID for efficacy and tolerability	Participants in this group had received double-blind asenapine 5 or 10 mg BID in preceding study P06124, and continued on same double-blind dose for first 6 weeks of extension study P06125, after which were re-randomized to open label asenapine 5 or 10 mg BID for 46 weeks. Open label dose could be adjusted using dose options of 5 and 10 mg BID for efficacy and tolerability
Period Title: Overall Study
STARTED	44	157
COMPLETED	15	71
NOT COMPLETED	29	86

Baseline Characteristics

Arm/Group Title	Placebo/Asenapine	Asenapine 5/10 mg BID	Total
Arm/Group Description	Participants in this group had received double-blind placebo BID in preceding study P06124, and continued on same double-blind dose for first 2 weeks of extension study P06125, then took double-blind asenapine 5 mg BID for 4 weeks, after which were re-randomized to open label asenapine 5 or 10 mg BID for 46 weeks. Open label dose could be adjusted using dose options of 5 and 10 mg BID for efficacy and tolerability	Participants in this group had received double-blind asenapine 5 or 10 mg BID in preceding study P06124, and continued on same double-blind dose for first 6 weeks of extension study P06125, after which were re-randomized to open label asenapine 5 or 10 mg BID for 46 weeks. Open label dose could be adjusted using dose options of 5 and 10 mg BID for efficacy and tolerability	Total of all reporting groups
Overall Participants	44	157	201
Age (years) [Mean (Standard Deviation) ]
Mean (Standard Deviation) [years]	42.50 (13.39)	41.82 (11.44)	41.97 (11.86)
Sex: Female, Male (Count of Participants)
Female	26 59.1%	79 50.3%	105 52.2%
Male	18 40.9%	78 49.7%	96 47.8%

Outcome Measures

1. Primary Outcome

Title	Percentage of Participants in Categories of Change in Weight From Study P06124 Baseline to Final Assessment
Description	For each participant, change in weight from preceding 6-week double-blind Study P06124 baseline to the final assessment of extension study P06125 was determined (calculated as final assessment value minus baseline value). Final assessment was last evaluation of participant in study, whether participant completed or did not complete study. Participants were allocated to categories of percentage change from defined baseline to final assessment.
Time Frame	Study P06124 baseline and P06125 study from Day 1 up to Week 52

Outcome Measure Data

Analysis Population Description

All participants randomized in study P06125 who received at least one dose of study drug, and had data for measure at study P06124 baseline and study P06125 final assessment

Arm/Group Title	Placebo/Asenapine	Asenapine 5/10 mg BID
Arm/Group Description	Participants in this group had received double-blind placebo BID in preceding study P06124, and continued on same double-blind dose for first 2 weeks of extension study P06125, then took double-blind asenapine 5 mg BID for 4 weeks, after which were re-randomized to open label asenapine 5 or 10 mg BID for 46 weeks. Open label dose could be adjusted using dose options of 5 and 10 mg BID for efficacy and tolerability	Participants in this group had received double-blind asenapine 5 or 10 mg BID in preceding study P06124, and continued on same double-blind dose for first 6 weeks of extension study P06125, after which were re-randomized to open label asenapine 5 or 10 mg BID for 46 weeks. Open label dose could be adjusted using dose options of 5 and 10 mg BID for efficacy and tolerability
Measure Participants	31	138
Increase ≥7%	12.9 29.3%	26.8 17.1%
Change within ± 7%	64.5 146.6%	61.6 39.2%
Decrease ≥7%	22.6 51.4%	11.6 7.4%

2. Primary Outcome

Title	Percentage of Participants in Categories of Change in Weight From Study P06125 Baseline to Final Assessment
Description	For each participant, change in weight from extension study P06125 baseline to the final assessment of extension study was determined (calculated as final assessment value minus baseline value). Final assessment was last evaluation of participant in study, whether participant completed or did not complete study. Participants were allocated to categories of percentage change from defined baseline to final assessment.
Time Frame	Study P06125 baseline up to Week 52

Outcome Measure Data

Analysis Population Description

All participants randomized in study P06125 who received at least one dose of study drug, and had data for measure at study P06125 baseline and final assessment

Arm/Group Title	Placebo/Asenapine	Asenapine 5/10 mg BID
Arm/Group Description	Participants in this group had received double-blind placebo BID in preceding study P06124, and continued on same double-blind dose for first 2 weeks of extension study P06125, then took double-blind asenapine 5 mg BID for 4 weeks, after which were re-randomized to open label asenapine 5 or 10 mg BID for 46 weeks. Open label dose could be adjusted using dose options of 5 and 10 mg BID for efficacy and tolerability	Participants in this group had received double-blind asenapine 5 or 10 mg BID in preceding study P06124, and continued on same double-blind dose for first 6 weeks of extension study P06125, after which were re-randomized to open label asenapine 5 or 10 mg BID for 46 weeks. Open label dose could be adjusted using dose options of 5 and 10 mg BID for efficacy and tolerability
Measure Participants	31	138
Increase ≥7%	22.6 51.4%	23.9 15.2%
Change within ± 7%	64.5 146.6%	62.3 39.7%
Decrease ≥7%	12.9 29.3%	13.8 8.8%

3. Primary Outcome

Title	Change From Study P06124 Baseline in Body Mass Index (BMI) at Week 52
Description	For each participant, change in BMI from preceding 6-week double-blind Study P06124 baseline to Week 52 of extension study P06125 was determined (calculated as Week 52 value minus baseline value).
Time Frame	Study P06124 baseline and study P06125 Week 52

Outcome Measure Data

Analysis Population Description

All participants randomized in study P06125 who received at least one dose of study drug, and had data for measure at study P06124 baseline and study P06125 Week 52

Arm/Group Title	Placebo/Asenapine	Asenapine 5/10 mg BID
Arm/Group Description	Participants in this group had received double-blind placebo BID in preceding study P06124, and continued on same double-blind dose for first 2 weeks of extension study P06125, then took double-blind asenapine 5 mg BID for 4 weeks, after which were re-randomized to open label asenapine 5 or 10 mg BID for 46 weeks. Open label dose could be adjusted using dose options of 5 and 10 mg BID for efficacy and tolerability	Participants in this group had received double-blind asenapine 5 or 10 mg BID in preceding study P06124, and continued on same double-blind dose for first 6 weeks of extension study P06125, after which were re-randomized to open label asenapine 5 or 10 mg BID for 46 weeks. Open label dose could be adjusted using dose options of 5 and 10 mg BID for efficacy and tolerability
Measure Participants	15	70
Mean (Standard Deviation) [kg/m^2]	-0.04 (2.83)	0.91 (2.74)

4. Primary Outcome

Title	Change From Study P06125 Baseline in BMI at Week 52
Description	For each participant, change in BMI from extension study P06125 baseline to Week 52 of extension study was determined (calculated as Week 52 value minus baseline value).
Time Frame	Study P06125 baseline and Week 52

Outcome Measure Data

Analysis Population Description

All participants randomized in study P06125 who received at least one dose of study drug, and had data for measure at study P06125 baseline and Week 52

Arm/Group Title	Placebo/Asenapine	Asenapine 5/10 mg BID
Arm/Group Description	Participants in this group had received double-blind placebo BID in preceding study P06124, and continued on same double-blind dose for first 2 weeks of extension study P06125, then took double-blind asenapine 5 mg BID for 4 weeks, after which were re-randomized to open label asenapine 5 or 10 mg BID for 46 weeks. Open label dose could be adjusted using dose options of 5 and 10 mg BID for efficacy and tolerability	Participants in this group had received double-blind asenapine 5 or 10 mg BID in preceding study P06124, and continued on same double-blind dose for first 6 weeks of extension study P06125, after which were re-randomized to open label asenapine 5 or 10 mg BID for 46 weeks. Open label dose could be adjusted using dose options of 5 and 10 mg BID for efficacy and tolerability
Measure Participants	15	70
Mean (Standard Deviation) [kg/m^2]	0.35 (2.48)	0.75 (2.41)

5. Primary Outcome

Title	Number of Participants With Extrapyramidal Symptoms
Description	This measure reports the overall number of participants with any of a group of adverse events that were defined to represent extrapyramidal symptoms. The number of participants with each of the individual adverse events within this definition is also presented, for terms that occurred in at least one participant. For this measure, all adverse event terms within the Medical Dictionary for Regulatory Activities (MedDRA) Standardized MedDRA Query (SMQ) for "extrapyramidal syndrome" were treated as extrapyramidal symptoms.
Time Frame	Up to 30 days after last dose of study drug (Up to approximately 56 weeks)

Outcome Measure Data

Analysis Population Description

All participants randomized in study P06125 who received at least one dose of study drug

Arm/Group Title	Placebo/Asenapine	Asenapine 5/10 mg BID
Arm/Group Description	Participants in this group had received double-blind placebo BID in preceding study P06124, and continued on same double-blind dose for first 2 weeks of extension study P06125, then took double-blind asenapine 5 mg BID for 4 weeks, after which were re-randomized to open label asenapine 5 or 10 mg BID for 46 weeks. Open label dose could be adjusted using dose options of 5 and 10 mg BID for efficacy and tolerability	Participants in this group had received double-blind asenapine 5 or 10 mg BID in preceding study P06124, and continued on same double-blind dose for first 6 weeks of extension study P06125, after which were re-randomized to open label asenapine 5 or 10 mg BID for 46 weeks. Open label dose could be adjusted using dose options of 5 and 10 mg BID for efficacy and tolerability
Measure Participants	44	157
Any extrapyramidal symptom	11 25%	34 21.7%
Restlessness	1 2.3%	2 1.3%
Akathisia	2 4.5%	13 8.3%
Bradykinesia	0 0%	2 1.3%
Dyskinesia	2 4.5%	3 1.9%
Dystonia	0 0%	2 1.3%
Extrapyramidal disorder	2 4.5%	6 3.8%
Parkinsonism	0 0%	1 0.6%
Tardive dyskinesia	0 0%	1 0.6%
Tremor	4 9.1%	6 3.8%
Parkinsonian gait	1 2.3%	0 0%
Oromandibular dystonia	1 2.3%	0 0%
Blepharospasm	1 2.3%	0 0%
Oculogyric crisis	0 0%	1 0.6%
Muscle rigidity	2 4.5%	1 0.6%
Muscle tightness	0 0%	1 0.6%
Musculoskeletal stiffness	1 2.3%	2 1.3%
Gait disturbance	0 0%	1 0.6%

6. Primary Outcome

Title	Change From Study P06124 Baseline in Drug-Induced Extrapyramidal Symptoms Scale (DIEPSS) Total Score at Endpoint
Description	Change in DIEPSS Total Score from preceding 6-week double-blind Study P06124 baseline to endpoint assessment of extension study P06125 was determined (calculated as endpoint value minus baseline value). Endpoint assessment was last evaluation of participant for this measure in study, whether participant completed or did not complete study. DIEPSS is a scale, rated by the investigator or rater appointed by the investigator, used to evaluate the severity of drug induced extrapyramidal symptoms occurring during antipsychotic drug treatment. It consists of 9 items: Items 1 through 8 assess individual symptoms; Item 9 is an assessment of global severity. Items 1 through 8 are classified into 4 categories of parkinsonism, akathisia, dystonia and dyskinesia. Each item is rated from 0 (none, normal) to 4 (severe). The Total Score is the sum of scores on Items 1 through 8, with a range from 0 (normal) to 32 (severe). Negative values of change from baseline represent improvement in symptoms.
Time Frame	Study P06124 baseline and P06125 study from Day 1 up to Week 52

Outcome Measure Data

Analysis Population Description

All participants randomized in study P06125 who received at least one dose of study drug, and had data for measure at study P06124 baseline and study P06125 endpoint assessment

Arm/Group Title	Placebo/Asenapine	Asenapine 5/10 mg BID
Arm/Group Description	Participants in this group had received double-blind placebo BID in preceding study P06124, and continued on same double-blind dose for first 2 weeks of extension study P06125, then took double-blind asenapine 5 mg BID for 4 weeks, after which were re-randomized to open label asenapine 5 or 10 mg BID for 46 weeks. Open label dose could be adjusted using dose options of 5 and 10 mg BID for efficacy and tolerability	Participants in this group had received double-blind asenapine 5 or 10 mg BID in preceding study P06124, and continued on same double-blind dose for first 6 weeks of extension study P06125, after which were re-randomized to open label asenapine 5 or 10 mg BID for 46 weeks. Open label dose could be adjusted using dose options of 5 and 10 mg BID for efficacy and tolerability
Measure Participants	44	153
Mean (Standard Deviation) [score on a scale]	-0.11 (1.99)	-0.46 (2.54)

7. Primary Outcome

Title	Change From Study P06125 Baseline in DIEPSS Total Score at Endpoint
Description	Change in DIEPSS Total Score from extension study P06125 baseline to the endpoint assessment of extension study was determined (calculated as endpoint value minus baseline value). Endpoint assessment was last evaluation of participant for this measure in study, whether participant completed or did not complete study. DIEPSS is a scale, rated by the investigator or rater appointed by the investigator, used to evaluate the severity of drug induced extrapyramidal symptoms occurring during antipsychotic drug treatment. It consists of 9 items: Items 1 through 8 assess individual symptoms; Item 9 is an assessment of global severity. Items 1 through 8 are classified into 4 categories of parkinsonism, akathisia, dystonia and dyskinesia. Each item is rated from 0 (none, normal) to 4 (severe). The Total Score is the sum of scores on Items 1 through 8, with a range from 0 (normal) to 32 (severe). Negative values of change from baseline represent improvement in symptoms.
Time Frame	Study P06125 baseline up to Week 52

Outcome Measure Data

Analysis Population Description

All participants randomized in study P06125 who received at least one dose of study drug, and had data for measure at study P06125 baseline and endpoint assessment

Arm/Group Title	Placebo/Asenapine	Asenapine 5/10 mg BID
Arm/Group Description	Participants in this group had received double-blind placebo BID in preceding study P06124, and continued on same double-blind dose for first 2 weeks of extension study P06125, then took double-blind asenapine 5 mg BID for 4 weeks, after which were re-randomized to open label asenapine 5 or 10 mg BID for 46 weeks. Open label dose could be adjusted using dose options of 5 and 10 mg BID for efficacy and tolerability	Participants in this group had received double-blind asenapine 5 or 10 mg BID in preceding study P06124, and continued on same double-blind dose for first 6 weeks of extension study P06125, after which were re-randomized to open label asenapine 5 or 10 mg BID for 46 weeks. Open label dose could be adjusted using dose options of 5 and 10 mg BID for efficacy and tolerability
Measure Participants	44	154
Mean (Standard Deviation) [score on a scale]	0.25 (1.57)	-0.03 (1.90)

8. Primary Outcome

Title	Change From Study P06124 Baseline in DIEPSS Item 9 Score at Endpoint
Description	Change in DIEPSS Item 9 (Global) Score from preceding 6-week double-blind Study P06124 baseline to endpoint assessment of extension study P06125 was determined (calculated as endpoint value minus baseline value). Endpoint assessment was last evaluation of participant for this measure in study, whether participant completed or did not complete study. DIEPSS is a scale, rated by the investigator or rater appointed by the investigator, used to evaluate the severity of drug induced extrapyramidal symptoms occurring during antipsychotic drug treatment. It consists of 9 items: Items 1 through 8 assess individual symptoms; Item 9 is an assessment of global severity. Each item is rated from 0 (none, normal) to 4 (severe). Negative values of change from baseline represent improvement in symptoms.
Time Frame	Study P06124 baseline and P06125 study from Day 1 up to Week 52

Outcome Measure Data

Analysis Population Description

All participants randomized in study P06125 who received at least one dose of study drug, and had data for measure at study P06124 baseline and study P06125 endpoint assessment

Arm/Group Title	Placebo/Asenapine	Asenapine 5/10 mg BID
Arm/Group Description	Participants in this group had received double-blind placebo BID in preceding study P06124, and continued on same double-blind dose for first 2 weeks of extension study P06125, then took double-blind asenapine 5 mg BID for 4 weeks, after which were re-randomized to open label asenapine 5 or 10 mg BID for 46 weeks. Open label dose could be adjusted using dose options of 5 and 10 mg BID for efficacy and tolerability	Participants in this group had received double-blind asenapine 5 or 10 mg BID in preceding study P06124, and continued on same double-blind dose for first 6 weeks of extension study P06125, after which were re-randomized to open label asenapine 5 or 10 mg BID for 46 weeks. Open label dose could be adjusted using dose options of 5 and 10 mg BID for efficacy and tolerability
Measure Participants	44	153
Mean (Standard Deviation) [score on a scale]	0.14 (0.63)	-0.01 (0.73)

9. Primary Outcome

Title	Change From Study P06125 Baseline in DIEPSS Item 9 Score at Endpoint
Description	Change in DIEPSS Item 9 (Global) Score from extension study P06125 baseline to the endpoint assessment of extension study was determined (calculated as endpoint value minus baseline value). Endpoint assessment was last evaluation of participant for this measure in study, whether participant completed or did not complete study. DIEPSS is a scale, rated by the investigator or rater appointed by the investigator, used to evaluate the severity of drug induced extrapyramidal symptoms occurring during antipsychotic drug treatment. It consists of 9 items: Items 1 through 8 assess individual symptoms; Item 9 is an assessment of global severity. Each item is rated from 0 (none, normal) to 4 (severe). Negative values of change from baseline represent improvement in symptoms.
Time Frame	Study P06125 baseline up to Week 52

Outcome Measure Data

Analysis Population Description

All participants randomized in study P06125 who received at least one dose of study drug, and had data for measure at study P06125 baseline and endpoint assessment

Arm/Group Title	Placebo/Asenapine	Asenapine 5/10 mg BID
Arm/Group Description	Participants in this group had received double-blind placebo BID in preceding study P06124, and continued on same double-blind dose for first 2 weeks of extension study P06125, then took double-blind asenapine 5 mg BID for 4 weeks, after which were re-randomized to open label asenapine 5 or 10 mg BID for 46 weeks. Open label dose could be adjusted using dose options of 5 and 10 mg BID for efficacy and tolerability	Participants in this group had received double-blind asenapine 5 or 10 mg BID in preceding study P06124, and continued on same double-blind dose for first 6 weeks of extension study P06125, after which were re-randomized to open label asenapine 5 or 10 mg BID for 46 weeks. Open label dose could be adjusted using dose options of 5 and 10 mg BID for efficacy and tolerability
Measure Participants	44	154
Mean (Standard Deviation) [score on a scale]	0.18 (0.69)	-0.02 (0.62)

10. Primary Outcome

Title	Change From Study P06124 Baseline in Glycosylated Hemoglobin (HbA1c) at Week 52
Description	For each participant, change in HbA1c from preceding 6-week double-blind Study P06124 baseline to Week 52 of extension study P06125 was determined (calculated as Week 52 value minus baseline value).
Time Frame	Study P06124 baseline and study P06125 Week 52

Outcome Measure Data

Analysis Population Description

All participants randomized in study P06125 who received at least one dose of study drug, and had data for measure at study P06124 baseline and study P06125 Week 52

Arm/Group Title	Placebo/Asenapine	Asenapine 5/10 mg BID
Arm/Group Description	Participants in this group had received double-blind placebo BID in preceding study P06124, and continued on same double-blind dose for first 2 weeks of extension study P06125, then took double-blind asenapine 5 mg BID for 4 weeks, after which were re-randomized to open label asenapine 5 or 10 mg BID for 46 weeks. Open label dose could be adjusted using dose options of 5 and 10 mg BID for efficacy and tolerability	Participants in this group had received double-blind asenapine 5 or 10 mg BID in preceding study P06124, and continued on same double-blind dose for first 6 weeks of extension study P06125, after which were re-randomized to open label asenapine 5 or 10 mg BID for 46 weeks. Open label dose could be adjusted using dose options of 5 and 10 mg BID for efficacy and tolerability
Measure Participants	15	68
Mean (Standard Deviation) [percentage of HbA1c]	-0.09 (0.44)	-0.02 (0.82)

11. Primary Outcome

Title	Change From Study P06125 Baseline in HbA1c at Week 52
Description	For each participant, change in HbA1c from extension study P06125 baseline to Week 52 of extension study was determined (calculated as Week 52 value minus baseline value).
Time Frame	Study P06125 baseline and Week 52

Outcome Measure Data

Analysis Population Description

All participants randomized in study P06125 who received at least one dose of study drug, and had data for measure at study P06125 baseline and Week 52

Arm/Group Title	Placebo/Asenapine	Asenapine 5/10 mg BID
Arm/Group Description	Participants in this group had received double-blind placebo BID in preceding study P06124, and continued on same double-blind dose for first 2 weeks of extension study P06125, then took double-blind asenapine 5 mg BID for 4 weeks, after which were re-randomized to open label asenapine 5 or 10 mg BID for 46 weeks. Open label dose could be adjusted using dose options of 5 and 10 mg BID for efficacy and tolerability	Participants in this group had received double-blind asenapine 5 or 10 mg BID in preceding study P06124, and continued on same double-blind dose for first 6 weeks of extension study P06125, after which were re-randomized to open label asenapine 5 or 10 mg BID for 46 weeks. Open label dose could be adjusted using dose options of 5 and 10 mg BID for efficacy and tolerability
Measure Participants	15	69
Mean (Standard Deviation) [percentage of HbA1c]	0.21 (0.36)	0.12 (1.02)

12. Primary Outcome

Title	Change From Study P06124 Baseline in Fasting Glucose at Week 52
Description	For each participant, change in fasting glucose from preceding 6-week double-blind Study P06124 baseline to Week 52 of extension study P06125 was determined (calculated as Week 52 value minus baseline value).
Time Frame	Study P06124 baseline and study P06125 Week 52

Outcome Measure Data

Analysis Population Description

All participants randomized in study P06125 who received at least one dose of study drug, and had data for measure at study P06124 baseline and study P06125 Week 52

Arm/Group Title	Placebo/Asenapine	Asenapine 5/10 mg BID
Arm/Group Description	Participants in this group had received double-blind placebo BID in preceding study P06124, and continued on same double-blind dose for first 2 weeks of extension study P06125, then took double-blind asenapine 5 mg BID for 4 weeks, after which were re-randomized to open label asenapine 5 or 10 mg BID for 46 weeks. Open label dose could be adjusted using dose options of 5 and 10 mg BID for efficacy and tolerability	Participants in this group had received double-blind asenapine 5 or 10 mg BID in preceding study P06124, and continued on same double-blind dose for first 6 weeks of extension study P06125, after which were re-randomized to open label asenapine 5 or 10 mg BID for 46 weeks. Open label dose could be adjusted using dose options of 5 and 10 mg BID for efficacy and tolerability
Measure Participants	14	64
Mean (Standard Deviation) [mmol/L]	0.37 (1.00)	0.28 (1.93)

13. Primary Outcome

Title	Change From Study P06125 Baseline in Fasting Glucose at Week 52
Description	For each participant, change in fasting glucose from extension study P06125 baseline to Week 52 of extension study was determined (calculated as Week 52 value minus baseline value).
Time Frame	Study P06125 baseline and Week 52

Outcome Measure Data

Analysis Population Description

All participants randomized in study P06125 who received at least one dose of study drug, and had data for measure at study P06125 baseline and Week 52

Arm/Group Title	Placebo/Asenapine	Asenapine 5/10 mg BID
Arm/Group Description	Participants in this group had received double-blind placebo BID in preceding study P06124, and continued on same double-blind dose for first 2 weeks of extension study P06125, then took double-blind asenapine 5 mg BID for 4 weeks, after which were re-randomized to open label asenapine 5 or 10 mg BID for 46 weeks. Open label dose could be adjusted using dose options of 5 and 10 mg BID for efficacy and tolerability	Participants in this group had received double-blind asenapine 5 or 10 mg BID in preceding study P06124, and continued on same double-blind dose for first 6 weeks of extension study P06125, after which were re-randomized to open label asenapine 5 or 10 mg BID for 46 weeks. Open label dose could be adjusted using dose options of 5 and 10 mg BID for efficacy and tolerability
Measure Participants	14	65
Mean (Standard Deviation) [mmol/L]	0.60 (1.79)	0.00 (2.16)

14. Primary Outcome

Title	Change From Study P06124 Baseline in Insulin at Week 52
Description	For each participant, change in insulin from preceding 6-week double-blind Study P06124 baseline to Week 52 of extension study P06125 was determined (calculated as Week 52 value minus baseline value).
Time Frame	Study P06124 baseline and study P06125 Week 52

Outcome Measure Data

Analysis Population Description

All participants randomized in study P06125 who received at least one dose of study drug, and had data for measure at study P06124 baseline and study P06125 Week 52

Arm/Group Title	Placebo/Asenapine	Asenapine 5/10 mg BID
Arm/Group Description	Participants in this group had received double-blind placebo BID in preceding study P06124, and continued on same double-blind dose for first 2 weeks of extension study P06125, then took double-blind asenapine 5 mg BID for 4 weeks, after which were re-randomized to open label asenapine 5 or 10 mg BID for 46 weeks. Open label dose could be adjusted using dose options of 5 and 10 mg BID for efficacy and tolerability	Participants in this group had received double-blind asenapine 5 or 10 mg BID in preceding study P06124, and continued on same double-blind dose for first 6 weeks of extension study P06125, after which were re-randomized to open label asenapine 5 or 10 mg BID for 46 weeks. Open label dose could be adjusted using dose options of 5 and 10 mg BID for efficacy and tolerability
Measure Participants	14	69
Mean (Standard Deviation) [μIU/mL]	4.06 (16.27)	2.24 (16.06)

15. Primary Outcome

Title	Change From Study P06125 Baseline in Insulin at Week 52
Description	For each participant, change in insulin from extension study P06125 baseline to Week 52 of extension study was determined (calculated as Week 52 value minus baseline value).
Time Frame	Study P06125 baseline and Week 52

Outcome Measure Data

Analysis Population Description

All participants randomized in study P06125 who received at least one dose of study drug, and had data for measure at study P06125 baseline and Week 52

Arm/Group Title	Placebo/Asenapine	Asenapine 5/10 mg BID
Arm/Group Description	Participants in this group had received double-blind placebo BID in preceding study P06124, and continued on same double-blind dose for first 2 weeks of extension study P06125, then took double-blind asenapine 5 mg BID for 4 weeks, after which were re-randomized to open label asenapine 5 or 10 mg BID for 46 weeks. Open label dose could be adjusted using dose options of 5 and 10 mg BID for efficacy and tolerability	Participants in this group had received double-blind asenapine 5 or 10 mg BID in preceding study P06124, and continued on same double-blind dose for first 6 weeks of extension study P06125, after which were re-randomized to open label asenapine 5 or 10 mg BID for 46 weeks. Open label dose could be adjusted using dose options of 5 and 10 mg BID for efficacy and tolerability
Measure Participants	14	69
Mean (Standard Deviation) [μIU/mL]	-5.61 (28.89)	0.56 (17.88)

16. Primary Outcome

Title	Change From Study P06124 Baseline in Prolactin at Week 52
Description	For each participant, change in prolactin from preceding 6-week double-blind Study P06124 baseline to Week 52 of extension study P06125 was determined (calculated as Week 52 value minus baseline value).
Time Frame	Study P06124 baseline and study P06125 Week 52

Outcome Measure Data

Analysis Population Description

All participants randomized in study P06125 who received at least one dose of study drug, and had data for measure at study P06124 baseline and study P06125 Week 52

Arm/Group Title	Placebo/Asenapine	Asenapine 5/10 mg BID
Arm/Group Description	Participants in this group had received double-blind placebo BID in preceding study P06124, and continued on same double-blind dose for first 2 weeks of extension study P06125, then took double-blind asenapine 5 mg BID for 4 weeks, after which were re-randomized to open label asenapine 5 or 10 mg BID for 46 weeks. Open label dose could be adjusted using dose options of 5 and 10 mg BID for efficacy and tolerability	Participants in this group had received double-blind asenapine 5 or 10 mg BID in preceding study P06124, and continued on same double-blind dose for first 6 weeks of extension study P06125, after which were re-randomized to open label asenapine 5 or 10 mg BID for 46 weeks. Open label dose could be adjusted using dose options of 5 and 10 mg BID for efficacy and tolerability
Measure Participants	15	70
Mean (Standard Deviation) [μg/L]	-37.46 (68.83)	-20.98 (47.14)

17. Primary Outcome

Title	Change From Study P06125 Baseline in Prolactin at Week 52
Description	For each participant, change in prolactin from extension study P06125 baseline to Week 52 of extension study was determined (calculated as Week 52 value minus baseline value).
Time Frame	Study P06125 baseline and Week 52

Outcome Measure Data

Analysis Population Description

All participants randomized in study P06125 who received at least one dose of study drug, and had data for measure at study P06125 baseline and Week 52

Arm/Group Title	Placebo/Asenapine	Asenapine 5/10 mg BID
Arm/Group Description	Participants in this group had received double-blind placebo BID in preceding study P06124, and continued on same double-blind dose for first 2 weeks of extension study P06125, then took double-blind asenapine 5 mg BID for 4 weeks, after which were re-randomized to open label asenapine 5 or 10 mg BID for 46 weeks. Open label dose could be adjusted using dose options of 5 and 10 mg BID for efficacy and tolerability	Participants in this group had received double-blind asenapine 5 or 10 mg BID in preceding study P06124, and continued on same double-blind dose for first 6 weeks of extension study P06125, after which were re-randomized to open label asenapine 5 or 10 mg BID for 46 weeks. Open label dose could be adjusted using dose options of 5 and 10 mg BID for efficacy and tolerability
Measure Participants	15	70
Mean (Standard Deviation) [μg/L]	10.91 (20.58)	-1.59 (17.22)

18. Primary Outcome

Title	Number of Participants With Serious Adverse Events (AEs)
Description	An AE is defined as any untoward medical occurrence in a participant administered study drug and which does not necessarily have to have a causal relationship with the study drug. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with study drug administration, whether or not considered related to study drug. A serious AE (SAE) is any AE occurring at any dose that results in death, is life-threatening, results in hospitalization or prolongation of hospitalization, results in persistent or significant disability/incapacity, or is a congenital anomaly/birth defect. In addition, an important medical event that may not result in death, be life-threatening, or require hospitalization may be considered an SAE when it may jeopardize the participant and may require medical or surgical intervention to prevent one of the outcomes listed in this definition.
Time Frame	Up to 30 days after last dose of study drug (Up to approximately 56 weeks)

Outcome Measure Data

Analysis Population Description

All participants randomized in study P06125 who received at least one dose of study drug

Arm/Group Title	Placebo/Asenapine	Asenapine 5/10 mg BID
Arm/Group Description	Participants in this group had received double-blind placebo BID in preceding study P06124, and continued on same double-blind dose for first 2 weeks of extension study P06125, then took double-blind asenapine 5 mg BID for 4 weeks, after which were re-randomized to open label asenapine 5 or 10 mg BID for 46 weeks. Open label dose could be adjusted using dose options of 5 and 10 mg BID for efficacy and tolerability	Participants in this group had received double-blind asenapine 5 or 10 mg BID in preceding study P06124, and continued on same double-blind dose for first 6 weeks of extension study P06125, after which were re-randomized to open label asenapine 5 or 10 mg BID for 46 weeks. Open label dose could be adjusted using dose options of 5 and 10 mg BID for efficacy and tolerability
Measure Participants	44	157
Number [participants]	5 11.4%	32 20.4%

19. Primary Outcome

Title	Number of Participants With Non-serious AEs
Description	An AE is defined as any untoward medical occurrence in a participant administered study drug and which does not necessarily have to have a causal relationship with the study drug. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with study drug administration, whether or not considered related to study drug. This measure presents the number of participants with at least one AEs that was non-serious (i.e., was not determined to be an SAE).
Time Frame	Up to 30 days after last dose of study drug (Up to approximately 56 weeks)

Outcome Measure Data

Analysis Population Description

All participants randomized in study P06125 who received at least one dose of study drug

Arm/Group Title	Placebo/Asenapine	Asenapine 5/10 mg BID
Arm/Group Description	Participants in this group had received double-blind placebo BID in preceding study P06124, and continued on same double-blind dose for first 2 weeks of extension study P06125, then took double-blind asenapine 5 mg BID for 4 weeks, after which were re-randomized to open label asenapine 5 or 10 mg BID for 46 weeks. Open label dose could be adjusted using dose options of 5 and 10 mg BID for efficacy and tolerability	Participants in this group had received double-blind asenapine 5 or 10 mg BID in preceding study P06124, and continued on same double-blind dose for first 6 weeks of extension study P06125, after which were re-randomized to open label asenapine 5 or 10 mg BID for 46 weeks. Open label dose could be adjusted using dose options of 5 and 10 mg BID for efficacy and tolerability
Measure Participants	44	157
Number [participants]	40 90.9%	131 83.4%

20. Primary Outcome

Title	Percentage of Participants With Abnormalities on Electrocardiogram (ECG) at Study P06124 Baseline, Study P06125 Baseline and Week 52
Description	The percentage of participants with abnormal ECG findings is reported for three time points: 6-week double-blind study P06124 baseline, extension study P06125 baseline and extension study Week 52.
Time Frame	Study P06124 baseline and P06125 study baseline and Week 52

Outcome Measure Data

Analysis Population Description

All participants randomized in study P06125 who received at least one dose of study drug

Arm/Group Title	Placebo/Asenapine	Asenapine 5/10 mg BID
Arm/Group Description	Participants in this group had received double-blind placebo BID in preceding study P06124, and continued on same double-blind dose for first 2 weeks of extension study P06125, then took double-blind asenapine 5 mg BID for 4 weeks, after which were re-randomized to open label asenapine 5 or 10 mg BID for 46 weeks. Open label dose could be adjusted using dose options of 5 and 10 mg BID for efficacy and tolerability	Participants in this group had received double-blind asenapine 5 or 10 mg BID in preceding study P06124, and continued on same double-blind dose for first 6 weeks of extension study P06125, after which were re-randomized to open label asenapine 5 or 10 mg BID for 46 weeks. Open label dose could be adjusted using dose options of 5 and 10 mg BID for efficacy and tolerability
Measure Participants	44	157
P06124 baseline (N = 43, 153)	41.9 95.2%	24.8 15.8%
P06125 baseline (N = 44, 156)	34.1 77.5%	26.9 17.1%
Week 52 (N = 14, 70)	42.9 97.5%	25.7 16.4%

21. Primary Outcome

Title	Number of Participants Who Took Antiparkinsonian Drugs
Description	This measure presents the number of participants who used antiparkinsonian drugs started on or after the start of study treatment in extension study P06125. Antiparkinsonian drugs were defined as those categorized into the N04 code (antiparkinson drugs) of the World Health Organization (WHO) Anatomical Therapeutic Chemical (ATC) classification system.
Time Frame	P06125 study from Day 1 up to Week 52

Outcome Measure Data

Analysis Population Description

All participants randomized in study P06125 who received at least one dose of study drug

Arm/Group Title	Placebo/Asenapine	Asenapine 5/10 mg BID
Arm/Group Description	Participants in this group had received double-blind placebo BID in preceding study P06124, and continued on same double-blind dose for first 2 weeks of extension study P06125, then took double-blind asenapine 5 mg BID for 4 weeks, after which were re-randomized to open label asenapine 5 or 10 mg BID for 46 weeks. Open label dose could be adjusted using dose options of 5 and 10 mg BID for efficacy and tolerability	Participants in this group had received double-blind asenapine 5 or 10 mg BID in preceding study P06124, and continued on same double-blind dose for first 6 weeks of extension study P06125, after which were re-randomized to open label asenapine 5 or 10 mg BID for 46 weeks. Open label dose could be adjusted using dose options of 5 and 10 mg BID for efficacy and tolerability
Measure Participants	44	157
Any antiparkinsonian drug	12 27.3%	40 25.5%
Biperiden	4 9.1%	8 5.1%
Biperiden hydrochloride	3 6.8%	16 10.2%
Procyclidine	2 4.5%	1 0.6%
Trihexyphenidyl	0 0%	3 1.9%
Trihexyphenidyl hydrochloride	1 2.3%	7 4.5%
Benzatropine mesilate	4 9.1%	5 3.2%

22. Primary Outcome

Title	Median Time to Loss of Effect in Responders
Description	Median time to loss of effect from P06125 extension study baseline was estimated using Kaplan-Meier product-limit method. Result reported in Responders, participants with ≥30% decrease from study P06124 baseline in Positive and Negative Syndrome Scale (PANSS, schizophrenia symptom scale) Total Score at the end of study P06124. Investigator or subinvestigator was to determine whether the study drug failed to maintain effect based on occurrence of any of the following: 1) Increase in PANSS Total Score ≥30% from P06125 extension study baseline, 2) Determination that participant's schizophrenic symptomatology had deteriorated requiring one or more of defined interventions (add new antipsychotic drug, increase in level of psychiatric outpatient care, or hospitalization/increase in level of hospitalization for psychiatric need), 3) Clinical Global Impression-Severity (CGI-S) score ≥6, 4) Discontinuation from study because of lack of efficacy, 5) AE/SAE of worsening of schizophrenia.
Time Frame	P06124 study baseline and Day 42, and P06125 study from Day 1 up to Week 52

Outcome Measure Data

Analysis Population Description

All participants randomized in study P06125 who received at least one dose of study drug, had PANSS measurement at P06125 baseline and at least one post-baseline PANSS measurement, and were study P06124 Responders

Arm/Group Title	Placebo/Asenapine	Asenapine 5/10 mg BID
Arm/Group Description	Participants in this group had received double-blind placebo BID in preceding study P06124, and continued on same double-blind dose for first 2 weeks of extension study P06125, then took double-blind asenapine 5 mg BID for 4 weeks, after which were re-randomized to open label asenapine 5 or 10 mg BID for 46 weeks. Open label dose could be adjusted using dose options of 5 and 10 mg BID for efficacy and tolerability	Participants in this group had received double-blind asenapine 5 or 10 mg BID in preceding study P06124, and continued on same double-blind dose for first 6 weeks of extension study P06125, after which were re-randomized to open label asenapine 5 or 10 mg BID for 46 weeks. Open label dose could be adjusted using dose options of 5 and 10 mg BID for efficacy and tolerability
Measure Participants	25	101
Median (95% Confidence Interval) [days]	357.0	177.0

23. Primary Outcome

Title	Median Time to Loss of Effect in Non-Responders
Description	Median time to loss of effect from P06125 extension study baseline was estimated using Kaplan-Meier product-limit method. Result reported in Non-Responders, participants without ≥30% decrease from study P06124 baseline in PANSS Total Score at the end of study P06124. Investigator or subinvestigator was to determine whether the study drug failed to maintain effect based on occurrence of any of the following: 1) Increase in PANSS Total Score ≥30% from P06125 extension study baseline, 2) Determination that participant's schizophrenic symptomatology had deteriorated requiring one or more of defined interventions (add new antipsychotic drug, increase in level of psychiatric outpatient care, or hospitalization/increase in level of hospitalization for psychiatric need), 3) Clinical Global Impression-Severity (CGI-S) score ≥6, 4) Discontinuation from study because of lack of efficacy, 5) AE/SAE of worsening of schizophrenia.
Time Frame	P06124 study baseline and Day 42, and P06125 study from Day 1 up to Week 52

Outcome Measure Data

Analysis Population Description

All participants randomized in study P06125 who received at least one dose of study drug, had PANSS measurement at P06125 baseline and at least one post-baseline PANSS measurement, and were study P06124 Non-Responders

Arm/Group Title	Placebo/Asenapine	Asenapine 5/10 mg BID
Arm/Group Description	Participants in this group had received double-blind placebo BID in preceding study P06124, and continued on same double-blind dose for first 2 weeks of extension study P06125, then took double-blind asenapine 5 mg BID for 4 weeks, after which were re-randomized to open label asenapine 5 or 10 mg BID for 46 weeks. Open label dose could be adjusted using dose options of 5 and 10 mg BID for efficacy and tolerability	Participants in this group had received double-blind asenapine 5 or 10 mg BID in preceding study P06124, and continued on same double-blind dose for first 6 weeks of extension study P06125, after which were re-randomized to open label asenapine 5 or 10 mg BID for 46 weeks. Open label dose could be adjusted using dose options of 5 and 10 mg BID for efficacy and tolerability
Measure Participants	19	52
Median (95% Confidence Interval) [days]	53.0	368.0

Adverse Events

Time Frame	Up to 30 days after last dose of study drug (Up to approximately 56 weeks)
Arm/Group Title	Placebo/Asenapine		Asenapine 5/10 mg BID
Arm/Group Description	Participants in this group had received double-blind placebo BID in preceding study P06124, and continued on same double-blind dose for first 2 weeks of extension study P06125, then took double-blind asenapine 5 mg BID for 4 weeks, after which were re-randomized to open label asenapine 5 or 10 mg BID for 46 weeks. Open label dose could be adjusted using dose options of 5 and 10 mg BID for efficacy and tolerability		Participants in this group had received double-blind asenapine 5 or 10 mg BID in preceding study P06124, and continued on same double-blind dose for first 6 weeks of extension study P06125, after which were re-randomized to open label asenapine 5 or 10 mg BID for 46 weeks. Open label dose could be adjusted using dose options of 5 and 10 mg BID for efficacy and tolerability
All Cause Mortality
	Placebo/Asenapine		Asenapine 5/10 mg BID
	Affected / at Risk (%)	# Events	Affected / at Risk (%)	# Events
Total	/ (NaN)		/ (NaN)
Serious Adverse Events
	Placebo/Asenapine		Asenapine 5/10 mg BID
	Affected / at Risk (%)	# Events	Affected / at Risk (%)	# Events
Total	5/44 (11.4%)		32/157 (20.4%)
Gastrointestinal disorders
Gastritis	0/44 (0%)		1/157 (0.6%)
Metabolism and nutrition disorders
Hyponatraemia	0/44 (0%)		1/157 (0.6%)
Polydipsia	0/44 (0%)		1/157 (0.6%)
Water intoxication	0/44 (0%)		1/157 (0.6%)
Musculoskeletal and connective tissue disorders
Muscle rigidity	0/44 (0%)		1/157 (0.6%)
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Lung cancer metastatic	0/44 (0%)		1/157 (0.6%)
Nervous system disorders
Neuroleptic malignant syndrome	0/44 (0%)		1/157 (0.6%)
Somnolence	0/44 (0%)		1/157 (0.6%)
Psychiatric disorders
Abnormal behaviour	0/44 (0%)		1/157 (0.6%)
Anxiety	0/44 (0%)		1/157 (0.6%)
Completed suicide	1/44 (2.3%)		0/157 (0%)
Depressed mood	1/44 (2.3%)		0/157 (0%)
Depression	0/44 (0%)		1/157 (0.6%)
Irritability	0/44 (0%)		1/157 (0.6%)
Panic attack	0/44 (0%)		1/157 (0.6%)
Restlessness	0/44 (0%)		1/157 (0.6%)
Schizophrenia	4/44 (9.1%)		22/157 (14%)
Sleep disorder	1/44 (2.3%)		0/157 (0%)
Stress	0/44 (0%)		1/157 (0.6%)
Suicidal ideation	0/44 (0%)		3/157 (1.9%)
Vascular disorders
Hypotension	1/44 (2.3%)		0/157 (0%)
Other (Not Including Serious) Adverse Events
	Placebo/Asenapine		Asenapine 5/10 mg BID
	Affected / at Risk (%)	# Events	Affected / at Risk (%)	# Events
Total	34/44 (77.3%)		98/157 (62.4%)
Cardiac disorders
Palpitations	3/44 (6.8%)		2/157 (1.3%)
Gastrointestinal disorders
Constipation	4/44 (9.1%)		12/157 (7.6%)
Hypoaesthesia oral	4/44 (9.1%)		1/157 (0.6%)
Stomatitis	4/44 (9.1%)		2/157 (1.3%)
Infections and infestations
Nasopharyngitis	6/44 (13.6%)		34/157 (21.7%)
Investigations
Aalanine aminotranferase increased	3/44 (6.8%)		8/157 (5.1%)
Weight increased	7/44 (15.9%)		17/157 (10.8%)
Metabolism and nutrition disorders
Hyperlipidaemia	3/44 (6.8%)		3/157 (1.9%)
Nervous system disorders
Akathisia	2/44 (4.5%)		13/157 (8.3%)
Dizziness	2/44 (4.5%)		9/157 (5.7%)
Headache	9/44 (20.5%)		9/157 (5.7%)
Somnolence	5/44 (11.4%)		17/157 (10.8%)
Tremor	4/44 (9.1%)		6/157 (3.8%)
Psychiatric disorders
Insomnia	2/44 (4.5%)		12/157 (7.6%)
Schizophrenia	6/44 (13.6%)		17/157 (10.8%)
Reproductive system and breast disorders
Dysmenorrhea	3/44 (6.8%)		1/157 (0.6%)
Skin and subcutaneous tissue disorders
Eczema	3/44 (6.8%)		5/157 (3.2%)
Pruritus	3/44 (6.8%)		4/157 (2.5%)

Limitations/Caveats

[Not Specified]

More Information

Certain Agreements

Principal Investigators are NOT employed by the organization sponsoring the study.

It is planned to first publish/present trial results together with the other sites, unless permission is obtained from Sponsor to publish separate results. Sponsor must be able to review all proposed results communications regarding study 45 days prior to submission for publication/presentation. If there is disagreement concerning appropriateness of the materials, Investigator and Sponsor must meet to make a good faith effort to discuss/resolve disagreement prior to submission for publication.